EN DE
Watch Nanjing Medlander Medical Technology Co. Ltd. A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nanjing Medlander Medical Technology Co. Ltd. A (688273) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Nanjing Medlander Medical Technology Co. Ltd. A stock ¥15.88, price ¥25.95, that is 38.8% below the price, quality 58 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100005PV8

NM Nanjing Medlander Medical Technology Co. Ltd. A logo Some data Nov 3, 2026

Nanjing Medlander Medical Technology Co. Ltd. A

688273 · SHG
Very expensive, in a downtrend

Our calculation puts a fair price 39% below what the stock costs today.

Solidly profitable · 19.7% net margin (TTM)
Quality 58/100
Expensive Growth (revenue 5y +5.1 %/yr in CNY)
3.1% dividend yield · Watch coverage
Mixed vs. peers (5/12)
Moderate moat 47/100 · thin data
Some data
Revenue last quarter 24% below a year ago.
Fair value ¥15.88 · Strongly overvalued (−38.8%)
Negative free cash flow
Watch Nanjing Medlander Medical Technology Co. Ltd. A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥60.51 ¥17.53 Fair Value ¥15.88 Aug 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

51‑month range ¥17.53 – ¥60.51 · fair‑value band ¥10.72 – ¥16.70 · the ¥25.95 price screens above the ¥15.88 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow Nanjing Medlander Medical Technology Co. Ltd. A in your weekly email

Every Wednesday you see whether Nanjing Medlander Medical Technology Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nanjing Medlander Medical Technology Co.,Ltd. engages in the research and development, manufacture, sale, and service of pelvic floor rehabilitation equipment and related products in China and internationally.

Show moreShow less

It offers pelvic floor and obstetrics and gynecology rehabilitation, reproductive rehabilitation and anti-aging product, and sports rehabilitation products, as well as consumables and IT products, such as vaginal electrodes, rectal electrodes, and vaginal probes.

The company also provides electronic colposcopes, biofeedback stimulation devices, high-frequency electrocautery devices, ultrasonic uterine involution devices, and electro-ultrasound therapy devices; and finger joint rehabilitation assessment systems, portable hand function rehabilitation assessment systems, hand function magnetic stimulation systems, transcranial magnetic stimulation systems, biofeedback devices, and portable biofeedback devices.

In addition, it provides pelvic floor muscle rehabilitation devices and power recliner. It serves clients in gynecology, obstetrics, rehabilitation, proctology, postpartum recovery centers, and urology areas. The company was founded in 2013 and is headquartered in Nanjing, China.

Stock analysis

Nanjing Medlander Medical Technology Co. Ltd. A (688273) currently trades at ¥25.95, while our model-based Fair Value estimate is ¥15.88, 39% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ¥24.02 per share, and 2 of the 15 models we run sit above the ¥25.95 price.

Bear case: the Asset-Based group reads lowest at ¥6.47, and 13 of the 15 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ¥10.72 (bear) to ¥16.70 (bull), the price of ¥25.95 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Nanjing Medlander Medical Technology Co. Ltd. A reported revenue of 432M CNY in FY2025 versus 342M CNY in FY2021, a compound +6.0%/yr. Reported net income was 103M CNY in FY2025, compounding −3.5%/yr from FY2021.

Key figures

Market cap 2.6B CNY (≈ $389M) Small · P/E ratio 32.4 · P/S ratio 6.77 · EPS (TTM) ¥0.8000 · Dividend yield 3.1% · Net margin 19.7% · Return on equity 5.2% · Return on assets (EBIT) 10.5% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).

What moves the price

The share trades about 57% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −39%, 688273 screens richer than that median.

Fair Value models

Bear ¥10.72 Fair Value ¥15.88 Bull ¥16.70
Price ¥25.95 · Downside -38.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ¥10.72 ¥11.29 ¥12.36 76
ROIC Compounder ¥15.11 ¥16.53 ¥18.08 70
EPV ¥14.91 ¥15.88 ¥16.70 68
All 15 models by family
Earnings-Based
Graham-Dodd ¥6.98 ¥18.10 ¥23.60 65
PEG = 1.0 ¥3.43 ¥4.90 ¥6.36 57
EPV ¥14.91 ¥15.88 ¥16.70 68
Dividend Discount
Gordon GGM ¥5.59 ¥10.06 ¥14.80 67
DDM Multi-Stage ¥5.59 ¥8.20 ¥10.73 67
Multiples
P/E Multiple ¥16.93 ¥22.58 ¥28.22 63
P/S Multiple ¥11.33 ¥15.11 ¥18.88 58
P/B Multiple ¥42.01 ¥56.01 ¥70.01 55
EV/EBIT ¥21.14 ¥25.46 ¥29.79 63
EV/EBITDA ¥21.96 ¥26.56 ¥31.16 64
EV/Revenue ¥17.23 ¥21.11 ¥25.00 52
Asset-Based
NCAV (Graham) ¥4.27 ¥6.47 ¥8.08 52
Economic Profit
Residual Income ¥10.72 ¥11.29 ¥12.36 76
ROIC Compounder ¥15.11 ¥16.53 ¥18.08 70
Growth Earnings
Growth-Adj P/E ¥13.15 ¥18.78 ¥24.42 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 58/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 45
How much profit the company makes from its sales and capital
Quality Growth 31
Are margins and returns getting better?
Cashflow 32
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 63
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Start year 2020 (pandemic)
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.5%
Dividend (yield on the price)3.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.40% → 24%

688273 screens overvalued: fair value 39% below the price. Compare with Abbott Laboratories, →

Compare Nanjing Medlander Medical Technology Co. Ltd. A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside −38.8% · Below median
Profitability
Return on equity (12 months) 5.2% · Above median
Return on assets 6.3% · Above median
Net margin (12 months) 19.7% · Top 25%
Operating margin (12 months) 8.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) −23.8% · Bottom 25%
Dividend yield (12 months) 3.1% · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 32.4× · Pricier than median
P/B 1.93× · Pricier than median
P/S (12 months) 6.77× · Priciest 25%
EV/EBITDA 25.6× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)21 · sector 17
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)62 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs 688273
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs 688273
DexCom, Inc DXCM $79.41 $87.35 +10% vs 688273
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs 688273
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs 688273
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs 688273
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs 688273
Abbott Laboratories, ABT $109.93 $75.28 −32% vs 688273
Medtronic plc MDT $101.80 $65.61 −36% vs 688273
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs 688273

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nanjing Medlander Medical Technology Co. Ltd. A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Nanjing Medlander Medical Technology Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688273

Frequently asked questions

Is Nanjing Medlander Medical Technology Co. Ltd. A (688273) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of ¥15.88 versus a price of ¥25.95, about 39% lower (overvalued).
What is the fair value of 688273?
Our model-based fair value for Nanjing Medlander Medical Technology Co. Ltd. A is ¥15.88 (as of Nov 3, 2026), built from audited fundamentals. The current price: ¥25.95.
What is the quality score of 688273?
Nanjing Medlander Medical Technology Co. Ltd. A has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Our model-based price target is the fair value of ¥15.88 (as of Nov 3, 2026) from 15 valuation models. Cautious scenario ¥10.72, optimistic scenario ¥16.70. It is a calculation from audited fundamentals, not an analyst target.
What is the Nanjing Medlander Medical Technology Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥15.88, about 39% lower versus a price of ¥25.95 (overvalued). Cautious scenario ¥10.72, optimistic scenario ¥16.70. The calculation is refreshed regularly with new filings.
What is the revenue of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Nanjing Medlander Medical Technology Co. Ltd. A reported trailing-twelve-month revenue of about 383M CNY (latest available figure, as of Nov 3, 2026).
Does Nanjing Medlander Medical Technology Co. Ltd. A pay a dividend?
Nanjing Medlander Medical Technology Co. Ltd. A currently shows a dividend yield of 3.08% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Nanjing Medlander Medical Technology Co. Ltd. A (688273) and when is the ex-dividend date?
Nanjing Medlander Medical Technology Co. Ltd. A pays a dividend of ¥0.8 per share a year, a dividend yield of 3.1%. The last ex-dividend date was May 26, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 100% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nanjing Medlander Medical Technology Co. Ltd. A it is ¥15.88 per share (as of Nov 3, 2026), against a price of ¥25.95. It is the blended result of 15 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Nanjing Medlander Medical Technology Co. Ltd. A stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 688273 trades above its calculated fair value: price ¥25.95, fair value ¥15.88, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688273?
No. The price is what the market pays today (¥25.95); the fair value is what the company's own numbers justify (¥15.88). For Nanjing Medlander Medical Technology Co. Ltd. A the two are ¥10.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nanjing Medlander Medical Technology Co. Ltd. A worth?
The market values Nanjing Medlander Medical Technology Co. Ltd. A at about 2.6B CNY (market capitalisation, as of Nov 3, 2026). Per share that is ¥25.95; our models calculate a fair value of ¥15.88 per share.
What do the bullish and bearish scenarios say about 688273?
Our models span a range for Nanjing Medlander Medical Technology Co. Ltd. A: cautious scenario ¥10.72, base ¥15.88, optimistic ¥16.70 per share (as of Nov 3, 2026, price ¥25.95). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688273?
Nanjing Medlander Medical Technology Co. Ltd. A trades at a price-to-earnings ratio of 32.4 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥15.88 is built from several models across several years. Other multiples: P/B 1.9, P/S 6.8, EV/EBITDA 25.6.
How solid is the balance sheet of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Balance-sheet figures for Nanjing Medlander Medical Technology Co. Ltd. A (as of Nov 3, 2026): return on equity 5.2%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 688273 from its 52-week high?
Nanjing Medlander Medical Technology Co. Ltd. A trades at ¥25.95, about 57% below its 52-week high of ¥60.51 and 6% above the low of ¥24.50 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥15.88 is for.
Which stocks are comparable to Nanjing Medlander Medical Technology Co. Ltd. A?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nanjing Medlander Medical Technology Co. Ltd. A stock attractive at the current price?
The data as of Nov 3, 2026: price ¥25.95, calculated fair value ¥15.88 (−39%), Quality Score 58/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688273 calculated?
We run Nanjing Medlander Medical Technology Co. Ltd. A through 15 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥15.88 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Nanjing Medlander Medical Technology Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The closing price on Nov 6, 2026 was ¥25.95. Our model-based fair value is ¥15.88, about 39% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nanjing Medlander Medical Technology Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥16.70). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Nanjing Medlander Medical Technology Co. Ltd. A

How large is the market capitalisation of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The market capitalisation of Nanjing Medlander Medical Technology Co. Ltd. A is 2.6B CNY (≈ $389M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The price-to-sales ratio of Nanjing Medlander Medical Technology Co. Ltd. A is 6.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Earnings per share at Nanjing Medlander Medical Technology Co. Ltd. A are ¥0.8000 (price ÷ EPS = P/E 32.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The dividend yield of Nanjing Medlander Medical Technology Co. Ltd. A is 3.1% (payout 100%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The net margin of Nanjing Medlander Medical Technology Co. Ltd. A is 19.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The return on equity (ROE) of Nanjing Medlander Medical Technology Co. Ltd. A is 5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
On an EBIT basis the return on assets of Nanjing Medlander Medical Technology Co. Ltd. A is 10.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The operating margin of Nanjing Medlander Medical Technology Co. Ltd. A is 8.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Revenue at Nanjing Medlander Medical Technology Co. Ltd. A is growing −23.8% versus a year earlier (3y avg +4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Earnings per share at Nanjing Medlander Medical Technology Co. Ltd. A are growing −42.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Nanjing Medlander Medical Technology Co. Ltd. A (688273) generate?
The free cash flow of Nanjing Medlander Medical Technology Co. Ltd. A is −12.7M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Nanjing Medlander Medical Technology Co. Ltd. A in the live analysis

One click puts Nanjing Medlander Medical Technology Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.